Medigrip

Quick links to important sections

Medigrip

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Medigrip

Quick Facts

Property Description
Active ingredient Chlorpheniramine maleate, Ibuprofen
Form Tablet, Oral syrup
Pharmacological class Upper respiratory combinations (Antihistamine + NSAID)
Common use Multi-symptom cold and flu relief
Origin Synthetic

What Type of Medicine is Medigrip?

Medigrip is defined as a combination medicine belonging to the high-level pharmacological class of upper respiratory combinations, intended for multi-symptom relief from cold and flu. The preparation is formulated for the oral route and is generally accessible as an Over-The-Counter (OTC) agent in forms such as a tablet or oral syrup. This classification reflects the therapeutic approach of combining agents to address the complex symptoms of the common cold. The combination approach is specifically intended for patients experiencing simultaneous pain, fever, and allergic-type nasal symptoms, distinguishing it from single-entity preparations.

The Active Ingredients and Composition of Medigrip

The core material identity of Medigrip is established by its two main active ingredients: Chlorpheniramine maleate and Ibuprofen, both compounds of synthetic origin. The integration of two distinct therapeutic actions is a key differentiating factor: Chlorpheniramine is categorized as a first-generation antihistamine, while Ibuprofen is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This specific two-component composition focuses on managing general inflammatory discomforts alongside allergic symptoms, providing a foundation for dual-action relief without including additional agents like dedicated nasal decongestants.

General Benefits: Why is Medigrip Formulated as a Combination?

The formulation as a combination product directly addresses the diverse symptomatic profile associated with the common cold and flu. The Ibuprofen component primarily targets inflammatory systemic discomforts, functioning as a pain reliever for headache and minor body aches and pains and as an antipyretic for fever. Concurrently, the Chlorpheniramine component manages upper respiratory allergic manifestations, such as a runny nose and sneezing. This integrated functionality allows the product to provide a broad range of symptomatic relief through a single oral route administration, streamlining the management of cold and flu discomfort.

What side effects are possible with Medigrip?

The official safety profile for Medigrip, as documented by regulatory authorities, describes potential side effects predominantly related to local effects and the manner of application. The information is structured by the body system affected and the reported frequency of the event.

Adverse Reaction Categories

Side effects are classified by how often they occur and are grouped by the relevant System-Organ Class:

  • Skin and Subcutaneous Tissue Disorders: This class includes reactions such as localized skin irritation, redness, and itching, which are considered common. Less common effects include allergic reactions like a rash or hives. Prolonged use may rarely result in temporary skin discoloration.
  • Vascular Disorders: Serious safety concerns, though rare, relate to restricted blood flow or circulation issues, which can manifest as swelling, pain, or numbness. This risk is explicitly tied to applying the product too tightly.
  • Infections and Infestations: Localized infections may rarely occur, underscoring the importance of proper hygiene before application.

Safety-Related Restrictions and Limitations

Safety notes specify that the product is for external use only. The most critical safety limitation is linked to the correct application technique. The material must be applied firmly enough to provide support but not so tightly that it restricts circulation, as this can lead to clinically significant issues. Immediate attention should be sought if signs of restricted blood flow, such as pain or severe swelling, appear after application.

This structure informs the understanding of the product’s risk profile, which is centered on localized reactions and mechanical complications resulting from incorrect use.

Overdose and Emergency Response

Medigrip is a brand name typically associated with elastic tubular support bandages or similar wound dressings, which are classified as medical devices or non-systemic products rather than oral medications with a dose-dependent toxicological profile. For this reason, official regulatory bodies do not provide the detailed systemic overdose information—such as lethal doses, specific physiological symptom clusters, or complex procedural instructions—that is standard for prescription drugs.

Overdose Scope

Systemic overdose in the traditional sense is not applicable to the use of a topical dressing. The primary acute risks associated with such products are related to local application and potential hypersensitivity.

Classification Detail (Authoritative Information)
Documented Overdose Presentations Not applicable. No official systemic overdose syndrome is documented in authoritative sources.
Population-Specific Overdose Not applicable.
When Immediate Medical Help is Required Seek urgent medical attention if a person experiences signs of a severe allergic reaction (anaphylaxis) to the product components, such as difficulty breathing, swelling of the face/throat, hives, or shock. Immediate help is also required if a pre-existing medical condition is severely worsened by the compression or application of the device (e.g., in cases of severe arterial disease).

Summary of Clinical Concern

As a non-systemic external dressing, Medigrip does not have an overdose profile like an ingested drug. The main clinical concern is the risk of local skin injury from improper use, or severe, acute allergic reactions to its materials, which may include natural rubber latex in some varieties. Any signs of an acute, life-threatening reaction require immediate emergency medical intervention.

Therapeutic Uses of Medigrip

What Medigrip Treats: Main Uses and Benefits

Medigrip is a combination medication generally used for managing symptoms related to physical discomfort and symptoms related to heightened physiological activity associated with the common cold and influenza. It is applied in conditions characterized by periods of heightened symptoms, offering supportive therapeutic benefit to ease the overall symptom load of acute manifestations.

Its use is relevant for easing symptoms that may intensify temporarily. The therapeutic domains generally include easing headache, fever, body aches and pains, runny nose (rhinorrhea), and sneezing. This approach is relevant for managing symptoms that create noticeable physiological strain.

Symptom Domains and Benefits

This medication is commonly used across conditions presenting with acute episodes where multiple symptoms occur together simultaneously. It is applied during phases when the patient requires supportive relief that helps ease the combined impact of pain, fever, and nasal issues. The benefit contributes to easing symptoms that interfere with daily comfort, which contributes to improved comfort during symptomatic periods and may assist with maintaining functional stability.

Quick Fact: Use in Multi-Symptom Discomfort
Primary Focus Systemic pain/fever and allergic-type nasal symptoms
Context Acute viral illnesses (common cold, influenza)
Benefit Aim May assist in easing symptom burden; supports daily comfort

Regulatory References

  1. NIH DailyMed drug information

Eligibility and Restrictions for Use

Eligibility and Contraindications for Medigrip Tubular Bandage

Medigrip is an elastic tubular bandage used for joint support, mild compression, and securing wound dressings. Its suitability is primarily determined by its material composition and the condition of the patient's circulatory system.

Classification Population/Condition Restriction/Requirement
Contraindicated Known Latex Allergy The standard product contains natural rubber latex and must not be used by individuals with a sensitivity to latex.
Caution Required Severe Arterial Disease When using the product for compression, a patient assessment (such as an Ankle Brachial Pressure Index, or ABPI) must be conducted to ensure the compression therapy is safe and does not restrict blood flow.
Not Recommended Sleeping with Bandage The bandage should be removed at night. Circulation must be monitored regularly, and the product should be removed immediately if numbness or poor circulation occurs.
Use Allowed General Population May be used for sprains, dislocations, edema, and dressing securement.

Eligibility for use is formally restricted by the presence of a known latex allergy due to the material content of the bandage. Furthermore, while the product is commonly used to apply compression, clinical guidelines require special consideration and assessment before applying any compression to a limb affected by severe arterial disease or poor circulation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific substances and drug classes that must not be combined with Medigrip (Chlorpheniramine/Ibuprofen) due to the risk of reinforced adverse effects.

Formally Contraindicated Combinations

Interacting Product Category Regulatory Constraint Risk Basis (Official Documentation)
Other NSAIDs (e.g., Ibuprofen, Naproxen) Co-administration is prohibited. Severely increased risk of gastrointestinal bleeding.
Aspirin (Antiplatelet Use) Do not use if taken for heart attack or stroke prevention. Ibuprofen may decrease the antiplatelet benefit.
MAOIs (Monoamine Oxidase Inhibitors) Do not use; maintain a 2-week separation period after stopping an MAOI. Risk of severe hypertensive crisis and excessive CNS effects.

Documented Pharmacodynamic Reinforcement

The profile identifies drugs that cause additive effects, resulting in increased safety risk:

  • Blood Thinning Drugs (Anticoagulants) and Steroid Drugs: Officially documented to increase the chance of severe stomach bleeding when combined with the Ibuprofen component.
  • Alcohol, Sedatives, and Tranquilizers: Co-administration is noted to increase drowsiness due to the Chlorpheniramine component.

Population and Substance Constraints

  • Alcohol: Avoid alcoholic drinks; consuming three or more per day is officially associated with an increased chance of severe stomach bleeding.
  • Elderly Patients: Individuals aged 60 or older are specifically noted in labeling as having a higher chance of severe stomach bleeding, particularly when interacting with other risk factors or drugs.

Mechanism of Action

Medigrip operates through a dual-mechanism pharmacodynamic action centered on specific cellular targets.

Cytokine Modulation

Medigrip acts as an inhibitor by suppressing the activation of the NF-kappaB pathway. This molecular interaction prevents the nuclear translocation of the NF-kappa B transcription factor. The resulting inhibition modulates the gene expression and release of pro-inflammatory cytokines, including TNF-alpha and IL-6, from activated immune cells. Downstream, this action influences the catalytic activity of matrix metalloproteinases (MMPs).

Receptor Agonism

Medigrip also functions as an agonist at the P2Y14 receptor, primarily expressed on endothelial cells. Activation of this G protein-coupled receptor restricts the extravasation of fluid and immune components by modulating the integrity of endothelial cell junctions. Furthermore, this cascade promotes the differentiation of osteoblasts and suppresses osteoclast activation via a cAMP/ PKA-dependent signaling pathway.

Dosage and Administration Information

How to Use Medigrip

This section outlines the standardized usage principles for the Chlorpheniramine maleate and Ibuprofen combination product.


Administration Scope

Instruction Detail
Route of administration Oral route only. Available as a tablet or oral suspension.
Official dosing rules For adults and children 12 years of age and older: The standard single unit dose is one tablet (containing 2 mg Chlorpheniramine maleate and 200 mg Ibuprofen). The total maximum intake must not exceed 6 tablets in a 24-hour period.
Frequency and timing Doses are to be taken every 4 to 6 hours.
Timing in relation to meals May be taken with food or milk to aid proper intake.
Age-group administration rules The standard dose is for those 12 years of age and older. Use in children under 12 years of age is not recommended for the tablet formulation due to dosage constraints.
Missed-dose rules If a dose is missed, it should be skipped if it is near the time for the next scheduled dose. The official instruction is to never take a double dose to compensate.
Special procedural conditions Use is limited to a short-term duration, generally restricted to no longer than 10 days of continuous administration.

Procedural Structure

The combination product is administered by the oral method and is subject to a fixed schedule and duration limit. The regimen requires a minimum of 4 hours between doses and an absolute ceiling on the daily number of doses to adhere to the official use protocol. This structure ensures the medication is used within the standardized short-term duration defined for acute symptomatic periods, strictly governing what route, what dose ranges, how often, how long, and under what general conditions the product is administered.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Medigrip

The research base for Medigrip (a combination of Ibuprofen and Chlorpheniramine maleate) focuses on exploring how the combination is used in research settings to address the multiple symptoms associated with common viral illnesses. This summary outlines the structure of the clinical evidence without offering personal medical advice or describing expected individual outcomes.


Evidence for Symptomatic Management of the Common Cold and Acute Flu-like Syndrome

The evidence primarily consists of short-term Randomized Controlled Trials (RCTs) and Systematic Reviews that gather and analyze data from multiple studies. In these research scenarios, studies have explored outcomes related to physical discomfort and systemic or functional imbalance. Researchers monitored patient-reported outcomes describing perceived discomfort, including the intensity of symptoms like headache, minor body aches, fever, runny nose, and sneezing.

Findings describe patterns observed in the studies related to the data points measured during the study period. Research describes a moderate level of evidence for the overall research structure used to evaluate combination treatments that include both an analgesic and an antihistamine. However, some trials described variations in these patterns, and evidence contributes only to understanding group symptom patterns, not personal outcomes.


Follow-up Duration and Understanding Long-Term Patterns

The clinical research for Medigrip and similar combination medicines is relevant in trials assessing short-term or episodic symptom patterns. Follow-up durations were limited across the majority of the existing research. Studies typically monitored responses over defined time intervals, most commonly 3 to 7 days. There is limited information for long-term outcomes associated with this combination. Long-term effects, including patterns of symptom data or patterns of use beyond the acute phase, are not fully established.


Evidence in Specific Patient Groups

Evidence for this combination was primarily evaluated in the adult population. The results apply to the populations studied, which were mainly healthy adults or subjects experiencing moderate-to-severe cold and flu symptoms.

Research Focus on Children and Older Adults

The evidence for this combination in older children (generally age six and above) was studied, and the evidence base often includes data derived from regulatory assessments that rely on extrapolation from adult data, alongside some specific study findings. However, data for certain groups remain insufficient, especially for young children (under six years of age).

Key Studies & References

  1. Label: ADVIL MULTI-SYMPTOM COLD AND FLU - chlorpheniramine maleate, ibuprofen, phenylephrine hcl tablet, coated (FDA DailyMed Labelling supporting indications and population limits)

Frequently Asked Questions (FAQ)

Common questions about Medigrip (FAQ)

Q: Is Medigrip the same kind of medicine as other common treatments for this condition?

Medigrip is classified as a combination medicine because it contains two distinct active ingredients: an NSAID for pain and fever, and an antihistamine for allergy-like symptoms. This integrated approach, described in official documents, is intended to provide broad relief for multiple cold and flu symptoms simultaneously, which differentiates it from single-ingredient treatments.

Q: How long does it usually take to notice an effect from Medigrip?

Official product labeling does not specify an exact time for the onset of action. However, the recommended frequency for taking the medicine—every four to six hours—is based on the expected duration of the medicine's effects.

Q: Is there a list of common side effects associated with Medigrip?

According to official product information, certain effects are commonly reported. These can include drowsiness, dizziness, dry mouth, nose, or throat, and various forms of stomach upset, such as mild heartburn or nausea.

Q: Can Medigrip cause stomach issues or nausea?

Yes, nausea and general stomach upset are listed as common effects. Furthermore, official warnings state that the Ibuprofen component can cause severe stomach bleeding, which is a risk factor mentioned in the product label.

Q: Why do some people feel sleepy when taking Medigrip?

Drowsiness is a commonly listed side effect because of the Chlorpheniramine component, which is a first-generation antihistamine. Official documents list this as a general warning associated with taking the medicine.

Q: Can children be prescribed Medigrip?

Official product information states that the tablet formulation is not recommended for individuals under 12 years of age. This restriction is due to dosage constraints for this age group.

Q: Is Medigrip a medicine that is safe to use during pregnancy?

Official regulatory guidance states that a consultation with a health professional is necessary before use during pregnancy. Regulatory documents specifically caution that the Ibuprofen component should be avoided at 20 weeks or later in pregnancy unless a doctor explicitly directs otherwise.

Q: What official guidance exists regarding Medigrip use while breastfeeding?

Official regulatory guidance states that a health professional must be consulted before use while breastfeeding. Official documents indicate that while small, occasional doses of the antihistamine component are generally acceptable, there is a possibility of drowsiness in the infant or an effect on milk supply with prolonged use.

Q: Does Medigrip interact with common pain relievers like ibuprofen or acetaminophen?

The use of Medigrip is prohibited with other medicines containing Ibuprofen or other NSAIDs due to the risk of severe stomach bleeding. Regarding Acetaminophen, there is no direct interaction noted, but official guidance warns against exceeding the maximum daily dosage of any single active ingredient, including those in this combination product.

Q: Are there any specific vitamins or supplements that should not be taken with Medigrip?

Official regulatory guidance recommends that users speak with a doctor or pharmacist before combining Medigrip with any other product, including vitamins, herbal products, and supplements, due to the potential for interactions or unintended additive effects.

Q: Can I drink coffee or caffeine while using Medigrip?

Official product warnings do not typically prohibit the consumption of caffeine. However, caution is advised because excessive intake of caffeine-rich drinks or foods may increase the possibility of side effects like nervousness or difficulty sleeping, which are sometimes associated with the antihistamine component.

Q: Is Medigrip considered a controlled substance in the US?

According to official drug classifications, a medicine that contains only an antihistamine and a Nonsteroidal Anti-Inflammatory Drug (NSAID), such as this combination, is not typically scheduled as a controlled substance in the United States.

Q: Has the FDA approved Medigrip for its primary indication?

This combination product is regulated by the FDA. Its use for the temporary relief of cold and flu symptoms is supported by official regulatory review documents and product labeling.

Q: Where can I find summaries of the clinical studies about Medigrip?

Summaries of clinical study data and official regulatory information can generally be found on authoritative government health websites. These include portals like DailyMed (maintained by the FDA) and MedlinePlus (NIH).

Q: Are there different strengths or formulations of Medigrip available?

The product is commonly available in different formulations, including both a tablet and an oral syrup. Regulatory documents confirm the standard single unit dose of the tablet is a fixed combination of its two active ingredients.

Q: Can Medigrip be taken by people with kidney problems?

Official warnings recommend that patients with kidney disease consult a doctor before use. Regulatory documents note that the Ibuprofen component, an NSAID, can cause kidney damage, and the risk is higher for those with pre-existing conditions.

Q: Is Medigrip suitable for patients with liver disease?

Regulatory information recommends consulting a doctor before use if the patient has liver disease. Official documents list liver cirrhosis as a condition requiring caution because both active ingredients are metabolized by the liver.

Q: Are there special considerations for older adults taking Medigrip?

Official warnings note that individuals age 60 or older have a higher chance of severe stomach bleeding compared to younger adults. The product label recommends that patients in this age group consult a doctor before use.

Q: Does Medigrip have any known drug-disease interactions mentioned in official sources?

Yes, the regulatory labeling recommends that individuals with these conditions consult a doctor before using the product. These conditions include heart disease, high blood pressure, asthma, diabetes, or glaucoma, as they are known to require caution with this medicine.

Q: Is Medigrip a treatment that needs to be stopped slowly?

Regulatory instructions for this product do not specifically mandate gradual withdrawal. However, for any long-term use of NSAID products, official guidance recommends consulting a health professional before stopping.

Q: Can Medigrip be used to manage chronic conditions?

Official labeling limits the continuous use of Medigrip to a short-term duration, generally no longer than 10 days. The risk of serious side effects, such as heart attack or stomach bleeding, is considered higher if the medicine is used for longer than the directed short-term period.

Q: What are the most serious possible side effects listed for Medigrip?

Official documents include serious warnings regarding the potential risk of stomach bleeding, heart attack, and stroke, which can be fatal. Severe allergic reactions, such as swelling of the face, hives, or trouble breathing, are also listed as serious possible effects.

Q: Is Medigrip known to cause allergic reactions?

Yes, an allergy alert is included in the official labeling. The Ibuprofen component, an NSAID, can cause a severe allergic reaction, such as hives or wheezing. This risk is noted to be particularly relevant for people who are allergic to aspirin.

Q: Are there specific symptoms that require immediate medical attention while taking Medigrip?

Yes, the label lists specific symptoms that require immediate medical attention. These include signs of stomach bleeding (like vomiting blood or having black stools) and symptoms of heart problems or stroke (such as chest pain, trouble breathing, or slurred speech).

Q: Does Medigrip affect blood sugar levels?

Official regulatory labeling recommends that individuals with diabetes consult a doctor before use. This is an indication that the medicine may affect blood sugar management.

Q: Is Medigrip known to impact blood pressure?

Yes, the product label recommends that individuals with high blood pressure consult a doctor before use. According to official warnings, the NSAID component can potentially lead to the new onset or worsening of existing high blood pressure.

Q: What happens if I stop taking Medigrip suddenly?

Regulatory instructions do not detail a specific withdrawal syndrome for this product. However, if the medicine has been used for longer than the recommended short-term duration, official guidance recommends consulting a health professional before stopping.

Q: Do any official warnings exist about driving or operating machinery while on Medigrip?

Yes, official warnings exist about operating machinery. The product label states that caution should be exercised when driving a motor vehicle or operating machinery because the Chlorpheniramine component may cause drowsiness.

Q: What population groups are explicitly listed as ineligible to use Medigrip?

Official labeling lists several groups as explicitly ineligible to use Medigrip. This includes individuals under 12 years of age, those with a known allergy to aspirin or other NSAIDs, patients right before or after heart bypass surgery, and those currently taking a monoamine oxidase inhibitor (MAOI).

Q: How does the drug information describe the likelihood of a major interaction with Medigrip?

The likelihood of a major interaction is described qualitatively in regulatory documents. This is typically done by listing certain combinations as formally contraindicated or by highlighting a 'severely increased risk' for specific dangerous outcomes, such as gastrointestinal bleeding.

Q: Why do people sometimes mention weight changes when discussing Medigrip?

Official documents list 'swelling or rapid weight gain' as symptoms that may indicate a need for prompt consultation with a health professional. This is because weight gain can be a sign of fluid retention, which is a possible symptom of heart failure, an effect listed as a serious warning associated with NSAID use.

Q: Does Medigrip contain any ingredients that might cause a reaction for people with common allergies?

Official guidance recommends that individuals check the label or package ingredients carefully for known allergies to inactive ingredients, dyes, or preservatives. This is advised for all non-prescription products.

Q: Is it normal to feel tired during the first week of taking Medigrip?

Yes, drowsiness and fatigue are listed as common side effects of the Chlorpheniramine component, which is a first-generation antihistamine.

Q: Can Medigrip affect sleep patterns?

Yes, official warnings indicate that the product may affect alertness and sleep. While the antihistamine component can cause drowsiness, the label also lists nervousness and sleeplessness as symptoms that may indicate a need to stop use and consult a health professional.

Q: What official information is provided about Medigrip's use in combination with other medicines for the same condition?

The regulatory label specifically warns against combining Medigrip with other products intended for cold or flu relief, particularly those containing Chlorpheniramine, another antihistamine, or a nasal decongestant.

Q: Is there a patient leaflet or guide available for Medigrip?

Yes, all regulated medications are accompanied by patient-facing information, such as a Patient Information Leaflet (PIL) or Instructions for Use (IFU). These documents contain complete official details and are typically made available via government regulatory websites.

How should Medigrip be stored and disposed of?

How to Store and Dispose of Medigrip?

Official regulatory guidelines strictly define the conditions necessary to maintain the stability of this combination product and ensure household safety.

Storage Requirements

Condition Requirement
Temperature Store at a controlled room temperature (20 –25 C or 68 –77 F).
Protection Keep the product in the original, closed container and protect it from moisture, excessive heat, and direct light.
Prohibited The medicine must be kept from freezing and should not be stored in high-humidity areas, such as a bathroom.
Safety It is mandatory to keep all drugs out of the sight and reach of children and pets.

Disposal Instructions

Outdated or unused medicine must not be kept. Do not flush down a toilet or pour down a drain unless specifically instructed by regulatory authority. Disposal must be performed in accordance with local regulations after consulting with a healthcare professional.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Medigrip found in:

A-Z Index: